FilingPulse

IKT insider transaction filings

Inhibikase Therapeutics, Inc. — 37 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-31. Screen IKT transaction legs live →

FiledFormInsiderReported transactionsSource
2026-07-314RA CAPITAL MANAGEMENT, L.P. — 10% owner
RA Capital Healthcare Fund LP — 10% owner
Kolchinsky Peter — 10% owner
Shah Rajeev M. — 10% owner		Other (J): 18,030,000 · Other (J): 18,030,000 (derivative)EDGAR
2026-07-314BERMAN DENNIS N — DirectorOption exercise (M): 21,854 @ $1.26 · Option exercise (M): 21,854 (derivative) @ $0EDGAR
2026-06-304Canner David — DirectorGrant/award (A): 155,000 (derivative) @ $0EDGAR
2026-06-304Kush Arvind — DirectorGrant/award (A): 155,000 (derivative) @ $0EDGAR
2026-06-304Bellini Roberto — DirectorGrant/award (A): 155,000 (derivative) @ $0EDGAR
2026-06-304Aurentz Vincent — DirectorGrant/award (A): 155,000 (derivative) @ $0EDGAR
2026-06-304Munshi Amit — DirectorGrant/award (A): 155,000 (derivative) @ $0EDGAR
2026-06-304BERMAN DENNIS N — DirectorGrant/award (A): 155,000 (derivative) @ $0EDGAR
2026-02-244Cabell Christopher — President & Head of R&DDisposition to issuer (D): 338,282 @ $0EDGAR
2026-02-244Aurentz Vincent — DirectorDisposition to issuer (D): 255,299 @ $0EDGAR
2026-02-244Munshi Amit — DirectorDisposition to issuer (D): 19,089 @ $0EDGAR
2026-01-074Cabell Christopher — President & Head of R&DGrant/award (A): 900,117 (derivative) @ $0EDGAR
2026-01-074Iwicki Mark T — Chief Executive Officer, DirectorGrant/award (A): 4,982,706 (derivative) @ $0EDGAR
2026-01-074McIntyre David — Chief Financial OfficerGrant/award (A): 986,319 (derivative) @ $0EDGAR
2025-11-244Sands Capital Life Sciences Pulse Fund II, L.P. — 10% owner
Sands Capital Alternatives, LLC — 10% owner
SANDS FRANK M. — 10% owner		Purchase (P): 2,068,965 @ $1.45EDGAR
2025-08-284Munshi Amit — DirectorGrant/award (A): 57,265 @ $0EDGAR
2025-07-024Canner David — DirectorGrant/award (A): 108,176 (derivative) @ $0EDGAR
2025-07-024Kush Arvind — DirectorGrant/award (A): 108,176 (derivative) @ $0EDGAR
2025-07-024Bellini Roberto — DirectorGrant/award (A): 108,176 (derivative) @ $0EDGAR
2025-07-024/ACabell Christopher — President & Head of R&DGrant/award (A): 1,100,705 (derivative) @ $0EDGAR
2025-07-024Aurentz Vincent — DirectorGrant/award (A): 108,176 (derivative) @ $0EDGAR
2025-07-024/AAurentz Vincent — DirectorGrant/award (A): 134,427 (derivative) @ $0EDGAR
2025-07-024Munshi Amit — DirectorGrant/award (A): 108,176 (derivative) @ $0EDGAR
2025-07-024/AIwicki Mark T — Chief Executive Officer, DirectorGrant/award (A): 602,346 (derivative) @ $0EDGAR
2025-07-024BERMAN DENNIS N — DirectorGrant/award (A): 108,176 (derivative) @ $0EDGAR
2025-04-164McIntyre David — Chief Financial OfficerGrant/award (A): 1,775,539 (derivative) @ $0EDGAR
2025-02-254Cabell Christopher — President & Head of R&DGrant/award (A): 1,100,705 (derivative) @ $0EDGAR
2025-02-254Aurentz Vincent — DirectorGrant/award (A): 134,427 (derivative) @ $0EDGAR
2025-02-254Iwicki Mark T — Chief Executive Officer, DirectorGrant/award (A): 602,346 (derivative) @ $0EDGAR
2025-02-194Kush Arvind — DirectorGrant/award (A): 56,600 (derivative) @ $0 · Grant/award (A): 116,585 (derivative) @ $0EDGAR
2025-02-194Bellini Roberto — DirectorGrant/award (A): 73,580 (derivative) @ $0 · Grant/award (A): 116,585 (derivative) @ $0EDGAR
2025-02-194Freeman Roy Lester — DirectorGrant/award (A): 22,640 (derivative) @ $0EDGAR
2025-02-194Canner David — DirectorGrant/award (A): 22,640 (derivative) @ $0 · Grant/award (A): 116,585 (derivative) @ $0EDGAR
2025-02-194Munshi Amit — DirectorGrant/award (A): 56,600 (derivative) @ $0 · Grant/award (A): 116,585 (derivative) @ $0EDGAR
2025-02-194Iwicki Mark T — Chief Executive Officer, DirectorGrant/award (A): 4,373,857 (derivative) @ $0 · Grant/award (A): 1,794,291 (derivative) @ $0EDGAR
2025-02-194BERMAN DENNIS N — DirectorGrant/award (A): 39,620 (derivative) @ $0EDGAR
2025-02-194/ABERMAN DENNIS N — DirectorGrant/award (A): 21,854 (derivative) @ $0 · Grant/award (A): 3,780 (derivative) @ $0 · Grant/award (A): 6,667 (derivative) @ $0 · Grant/award (A): 6,667 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0EDGAR

Recent 8-K events — Inhibikase Therapeutics, Inc.

FiledFormItems reportedSource
2026-08-118-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-07-298-K3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits		EDGAR
2026-07-238-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits		EDGAR
2026-07-148-K8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2026-06-298-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits		EDGAR
2026-05-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2026-04-078-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits		EDGAR
2026-03-268-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits		EDGAR
2025-12-198-K8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
2025-11-218-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits		EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=IKT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →